Prelude Partners with Lilly to Test KAT6A Degrader in Breast Cancer Trial
Event summary
- Prelude Therapeutics has partnered with Lilly to evaluate PRT13722, a KAT6A selective degrader, in combination with Lilly’s Verzenio® and Inluriyo® in a Phase 1 trial for HR+/HER2- breast cancer.
- The trial is expected to begin enrolling patients in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.
- Preclinical data show PRT13722 demonstrates monotherapy efficacy and synergy with CDK4/6 inhibitors and endocrine therapies across multiple HR+ breast cancer models.
- Prelude maintains full global development and commercial rights to PRT13722.
The big picture
This collaboration underscores the growing focus on targeted protein degradation in oncology, particularly for HR+/HER2- breast cancer. By partnering with Lilly, a leader in breast cancer treatments, Prelude aims to enhance the therapeutic potential of PRT13722, potentially setting a new standard for combination therapies in earlier lines of treatment. The strategic move highlights the industry’s shift toward more selective and tolerable treatments, addressing unmet needs in precision oncology.
What we're watching
- Clinical Progress
- How the Phase 1 trial results will validate PRT13722’s efficacy and safety in combination with Lilly’s therapies.
- Regulatory Pathway
- Whether the FDA’s clearance for the Phase 1 study will expedite future regulatory approvals for PRT13722.
- Commercial Strategy
- The pace at which Prelude can leverage this partnership to expand its pipeline and commercialize PRT13722 globally.
Related topics
